Just one month after launch, five early-stage science companies have moved into the Leap incubator lab space at ARC West London. The first cohort of innovators joining Leap includes: Solveteq, Reseda Life Sciences, Tachmed, IgEDAPT, and Sea2Carbon.
In this blog, Ethan Almond, Content & Communications Executive at BIA, explores the influence of the BIA’s bioProcessUK conference. The 22nd edition highlighted the UK’s leadership in bioprocessing.
The BioIndustry Association (BIA) released From Innovation to Impact: Unlocking Patient Access to Innovative Rare Disease Medicines, calling for new pathway to give UK patients access to innovative rare disease medicines.
More than 110,000 people in the UK live with a muscle-wasting condition which gradually damages the way their muscles work. Over time, it stops them from living everyday life. In some cases, lives will be cut short. Through this partnership, the BIA will leverage the network it has fostered in the UK life sciences and biotech sector to support those affected by muscle-wasting conditions.
Autolus Therapeutics plc, an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the National Institute for Health and Care Excellence (NICE) has published draft guidance recommending AUCATZYL® (obecabtagene autoleucel, or “obe-cel”) for use in the National Health Service (NHS) in England and Wales as a treatment option for adult patients (≥26 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity. Under the CNPV expedited program, review is expected within 1–2 months following the FDA’s acceptance of the filing.
Sai Life Sciences, Agility Life Sciences, and Centrix Pharma Solutions announce an ‘Integrated CMC Partnership’ to accelerate drug development for innovators.
Senior leaders from PHTA and Clinical Immunology Services took home the top prizes in two prestigious categories at the West Midlands Innovation Awards
Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.
London Life Sciences Week was a huge success last week, with significant increase in investors and life sciences execs coming together to connect and network. Combined with the news of two new significant fund raises from Sofinnova and Medicxi and progress towards completion of the British Growth Partnership Fund, it did feel that the sector found a lot to be hopeful about.
T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, today announces the successful expansion of its Series A financing, raising afurther $32 million. Following the initial $59 million raised, this brings the Series A total to date to $91 million.
The British Business Bank has announced a €30 million commitment to Sofinnova Partners (Sofinnova) new €650 million ($750 million) fund, Sofinnova Capital XI.
London Life Sciences Week kicked off last night with a buzzing reception at Somerset House and we’re looking forward to a jam-packed week of networking and events. Great to see the incredible hard work from the BIA and L&P teams come to life – shining a global light on the incredible UK ecosystem. At the same time, we’re seeing the UK take a leading role in pro-innovation regulation, from last week’s enactment of the Precision Breeding Act to Lawrence Tallon’s insights on the MHRA’s proportionate, strategic future approach, and now need the government to invest in the sector and ensure the commercial environment enables the UK to build on this world-beating foundation.
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, today announced it has joined the American Heart Association Center for Health Technology & Innovation’s Innovators’ Network.
It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch.
In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.
The UK’s life sciences sector has always been defined by its pioneering spirit. Today, that spirit is driving a revolution in medicine, with mRNA technology at its core. This report serves as a testament to the remarkable progress we have made in the UK, moving from a field of great promise to a strategic national asset.
September has got off to a busy start at BIA, with significant raises, deals, expansion and M&A activity for members; welcoming our US counterparts to London, closely monitoring UK political shuffles and the party conference action as that kicks off with Reform and some unwelcome anti-vaccine misinformation.
Brainomix, a global leader and pioneer of AI-powered imaging tools in stroke and lung fibrosis, has garnered widespread media attention1 this week following a renewed focus on the impact of its Brainomix 360 Stroke technology to improve recovery rates for stroke patients.
Pioneer Group, a specialist in life science infrastructure and venture building, has launched a new Accelerator Programme for early-stage life science companies targeting unmet needs in the management of chronic conditions.
